admin
I'm here for our amazing Cancer Warriors!

Preview

Kidney Cancer Experts at UT Southwestern discuss the CARMENA trial
Kidney Cancer Experts at UT Southwestern discuss the CARMENA trial
superboy

Preview

Targeting RCC Metabolism: Glutaminase Inhibition
Targeting RCC Metabolism: Glutaminase Inhibition
TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers
TIL products from Renal Cell Carcinomas are tumor-specific but poor cytokine producers
NEW TARGETS IN RCC
NEW TARGETS IN RCC
Novel epigenetic targeting approaches
Novel epigenetic targeting approaches
HIF-2aa new target in metastatic RCC
HIF-2a a new target in metastatic RCC
Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma
Randomised phase 2 study of sapanisertib (TAK?228/MLN0128) ± TAK-117 versus everolimus in patients with VEGF-targeted therapy-refractory metastatic clear cell renal cell carcinoma
imedex

Preview

CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity
CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity
Update: Relapsed/Refractory Follicular Lymphoma
Update: Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma: Update on Upfront and Maintenance Therapy
Follicular Lymphoma: Update on Upfront and Maintenance Therapy
CAR-T in Lymphoma
CAR-T in Lymphoma
Peripheral T-Cell Lymphoma: What is New on the Horizon?
Peripheral T-Cell Lymphoma: What is New on the Horizon?
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
patientpower

Preview

giuspeppe curigliano ITALIAN video 1
giuspeppe curigliano ITALIAN video 1
giuspeppe curigliano ITALIAN video 3
giuspeppe curigliano ITALIAN video 3
giuspeppe curigliano ITALIAN video 4
giuspeppe curigliano ITALIAN video 4
giuspeppe curigliano ITALIAN video 2
giuspeppe curigliano ITALIAN video 2
colombo ITALIÀ video 1-
colombo ITALIÀ video 1-
colombo ITALIÀ video 2
colombo ITALIÀ video 2

Preview

Introduction & Individualizing Treatment for Your Patients with RRMM: Selecting Among the Available Options
Introduction & Individualizing Treatment for Your Patients with RRMM: Selecting Among the Available Options
Optimal Strategies for the Identification and Management of Treatment-Related Adverse Events
Optimal Strategies for the Identification and Management of Treatment-Related Adverse Events
Improving Practice and Future Perspectives: Panel Discussion
Improving Practice and Future Perspectives: Panel Discussion
gistonline

Preview

Domande e discussione col pubblico a seguito della presentazione “Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche”
Domande e discussione col pubblico a seguito della presentazione “Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche”
Prof. Loris Pironi, Direttore Centro di Riferimento Regionale per l'Insufficienza Intestinale Cronica Benigna, Policlinico S. Orsola-Malpighi, Università di Bologna
Prof. Loris Pironi, Direttore Centro di Riferimento Regionale per l'Insufficienza Intestinale Cronica Benigna, Policlinico S. Orsola-Malpighi, Università di Bologna
Dott. Paolo G. Casali, Responsabile SSD Oncologia Medica Tumori Mesenchimali dell'Adulto, Fondazione IRCCS Istituto Nazionale Tumori – Milano
Dott. Paolo G. Casali, Responsabile SSD Oncologia Medica Tumori Mesenchimali dell'Adulto, Fondazione IRCCS Istituto Nazionale Tumori – Milano
Dott.ssa Maria A. Pantaleo, SSD Oncologia Medica-Biasco, AO Universitaria Policlinico Sant'Orsola Malpighi, Università di Bologna
Dott.ssa Maria A. Pantaleo, SSD Oncologia Medica-Biasco, AO Universitaria Policlinico Sant'Orsola Malpighi, Università di Bologna
Domande e discussione con il pubblico a seguito della presentazione &quotTerapia con Regorafenib in terza linea di trattamento"
Domande e discussione con il pubblico a seguito della presentazione "Terapia con Regorafenib in terza linea di trattamento"
Dott.ssa Elena Fumagalli, SSD Oncologia Medica Tumori Mesenchimali dell'Adulto, Fondazione IRCCS Istituto Nazionale Tumori - Milano
Dott.ssa Elena Fumagalli, SSD Oncologia Medica Tumori Mesenchimali dell'Adulto, Fondazione IRCCS Istituto Nazionale Tumori - Milano
roswellpark

Preview

Back Pain and Cancer
Back Pain and Cancer
Indications for Kyphoplasty and Vertebroplasty
Indications for Kyphoplasty and Vertebroplasty
Next-Generation Sequencing for Oncologists
Next-Generation Sequencing for Oncologists
How to Choose Your Cancer Surgeon
How to Choose Your Cancer Surgeon
Fundamentals of Cancer Immunotherapy
Fundamentals of Cancer Immunotherapy
Unique Clinical Trial Involves New Adoptive T Cell Therapy
Unique Clinical Trial Involves New Adoptive T Cell Therapy
vhsimons

Preview

Dr. Tewari Racial Disparities in Pca
Dr. Tewari Racial Disparities in Pca
African-American Prostate Cancer
African-American Prostate Cancer
Active Surveillance in High Risk populations
Active Surveillance in High Risk populations
The new Mo stage for Prostate Cancer progression
The new Mo stage for Prostate Cancer progression
PARP Inhibitors and Prostate Cancer
PARP Inhibitors and Prostate Cancer
Immunotherapy and Prostate Cancer
Immunotherapy and Prostate Cancer
kidneycancer

Preview

Novel Oral HIF-2 Alpha Inhibitor PT2977
Novel Oral HIF-2 Alpha Inhibitor PT2977
mTOR & PI3 Kinase Inhibitor Study
mTOR & PI3 Kinase Inhibitor Study
No OS Signal in Axitinib + Avelumab Combination Therapy
No OS Signal in Axitinib + Avelumab Combination Therapy
Remembering Martin Gore
Remembering Martin Gore
Discussing Debate On Cytoreductive Nephrectomy
Discussing Debate On Cytoreductive Nephrectomy
Neoadjuvant Trials In Kidney Cancer
Neoadjuvant Trials In Kidney Cancer
oncozine

Preview

Pediatric Oncology | Childhood Cancer
Pediatric Oncology | Childhood Cancer
Breast Cancer facts
Breast Cancer facts
Early-stage Breast Cancer and Patients' Risk of Disease Recurrence
Early-stage Breast Cancer and Patients' Risk of Disease Recurrence
African-American Women and Breast Cancer Risk
African-American Women and Breast Cancer Risk
Gene Called USP9X and Tamoxifen Resistance
Gene Called USP9X and Tamoxifen Resistance
Molecular Subtyping Improves Breast Cancer Treatment
Molecular Subtyping Improves Breast Cancer Treatment
feeds

Preview

5d5f57af9bea8
5d5f57af9bea8
Test
Test
Test
Test
3-9-14   9:01am
3-9-14 9:01am
3-9-14   8:50am
3-9-14 8:50am
3-7-14  10:54 FLV
3-7-14 10:54 FLV

Preview

@OncEd Presents Dr. Barb Melosky - Best of Lung Cancer - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Barb Melosky - Best of Lung Cancer - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Winson Cheung - Best of Health Services / Survivorship - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Winson Cheung - Best of Health Services / Survivorship - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Scott North - Best of Prostate - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Scott North - Best of Prostate - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Christian Kollmannsberger - Best of Non-Prostate - best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Christian Kollmannsberger - Best of Non-Prostate - best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Stephen Chia - Best of Breast Cancer - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Stephen Chia - Best of Breast Cancer - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Michael Smylie - Best of Melanoma - Best of Annual Meeting 2015 Vancouver
@OncEd Presents Dr. Michael Smylie - Best of Melanoma - Best of Annual Meeting 2015 Vancouver
cancergrace
The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care.

Preview

Supportive Care Video Series 2019 - Chemotherapy Induced Peripheral Neuropathy
Supportive Care Video Series 2019 - Chemotherapy Induced Peripheral Neuropathy
Paying for Oral Targeted Therapies -  Targ Ther 2019
Paying for Oral Targeted Therapies - Targ Ther 2019
Targeted Therapies 2019 Intro and NGS START
Targeted Therapies 2019 Intro and NGS START
ASCO 2019 LC RoundTable - Thoughts on KRAS G12D as a Target
ASCO 2019 LC RoundTable - Thoughts on KRAS G12D as a Target
ASCO 2019 Lung Cancer Round Table - Stage IV NSCLC - New Targets:  RET
ASCO 2019 Lung Cancer Round Table - Stage IV NSCLC - New Targets: RET
ASCO 2019 Lung Cancer Round Table - Stage IV NSCLC  New Targets  MET
ASCO 2019 Lung Cancer Round Table - Stage IV NSCLC New Targets MET
moasc

Preview

Determination from the FDA
Determination from the FDA
The Role of Nephrectomy
The Role of Nephrectomy
ENZAMET and TITAN Study
ENZAMET and TITAN Study
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
CheckMate 204 Study
CheckMate 204 Study
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
coa

Preview

COA Files Lawsuit Against Federal Government to Stop Sequester Cut to Cancer Drug Reimbursement
COA Files Lawsuit Against Federal Government to Stop Sequester Cut to Cancer Drug Reimbursement
Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices
Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices
Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position
Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position
Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations
Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations
A Conversation with Joan Lunden: Three Takeaways
A Conversation with Joan Lunden: Three Takeaways
People Helping People: Scott Hamilton on the Cancer Care Team
People Helping People: Scott Hamilton on the Cancer Care Team
SITC

Preview

Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope™?
Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope™?
robertflane

Preview

The Bell Lap Diaries - Cancers Wind Runners
The Bell Lap Diaries - Cancers Wind Runners
rajkumar

Preview

SampleVideo_720x480_1mb
SampleVideo_720x480_1mb
SampleVideo_720x480_1mb
SampleVideo_720x480_1mb
SampleVideo_720x480_2mb
SampleVideo_720x480_2mb
SampleVideo_720x480_2mb
SampleVideo_720x480_2mb
New Principle in Breast Cancer Chemotherapy
New Principle in Breast Cancer Chemotherapy
The first article
The first article
ADCReview

Preview

Changing Strategies in the ‘War on Cancer’ - Part 3: Improving Outcomes in the Treatment of Breast Cancer
Changing Strategies in the ‘War on Cancer’ - Part 3: Improving Outcomes in the Treatment of Breast Cancer
Changing Strategies in the ‘War on Cancer’ - Part 2: The Complexities in Manufacturing Highly Potent Anti-Cancer Medicines
Changing Strategies in the ‘War on Cancer’ - Part 2: The Complexities in Manufacturing Highly Potent Anti-Cancer Medicines
Changing Strategies in the War on Cancer (Part 1)
Changing Strategies in the War on Cancer (Part 1)
Antibody-drug Conjugates - Where are we now?
Antibody-drug Conjugates - Where are we now?
ADC Review / Journal of Antibody-drug Conjugates (Intro/leader)
ADC Review / Journal of Antibody-drug Conjugates (Intro/leader)
EMJ

Preview

Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer

Preview

Clinical Interventional Oncology (CIO)
Clinical Interventional Oncology (CIO)
AudioMedica

Preview

Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies
Tumour heterogeneity — clonal evolution of cancer limits effectiveness of targeted systemic therapies
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia
HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation
HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation
Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective
Castration-resistant prostate cancer with bone metastases: long follow up shows radium is safe as well as effective
Enzalutamide significantly improves survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer
Enzalutamide significantly improves survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer
PVReporter

Preview

Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2
Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter, part 2
Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter
Dr. Jean Jacques Kiladjian ASH 2018 interview with David Wallace, PV Reporter
Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter
Dr. Michael Grunwald ASH 2018 interview with David Wallace, PV Reporter
PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017
PV Reporter Interviews Dr. Jean Jacques Kiladjian at ASH 2017
PV Reporter interviews Dr. Raajit Rampal at ASH 2017
PV Reporter interviews Dr. Raajit Rampal at ASH 2017
PV Reporter interviews Dr. Michael Grunwald at ASH 2017
PV Reporter interviews Dr. Michael Grunwald at ASH 2017
oncbiz

Preview

Ray Bailey, PharmD talks about The Role of In House Pharmacies for oncology practices
Ray Bailey, PharmD talks about The Role of In House Pharmacies for oncology practices
Dr. Siddhartha Mukherjee - The Emperor of All Maladies
Dr. Siddhartha Mukherjee - The Emperor of All Maladies
Dr. John Pwderly discusses Molecular Profiling at COA
Dr. John Pwderly discusses Molecular Profiling at COA
obr

Preview

Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Landscape of Metastatic Hormone-Sensitive Prostate Cancer
Most Anticipated Trial Results Regarding Biomarkers in RCC
Most Anticipated Trial Results Regarding Biomarkers in RCC
Strategies for Treating RCC in the 2nd Line Setting
Strategies for Treating RCC in the 2nd Line Setting
Perspective on Treating Newly Diagnosed RCC Patients
Perspective on Treating Newly Diagnosed RCC Patients
Studies in Sarcomatoid RCC and Urothelial Cancer
Studies in Sarcomatoid RCC and Urothelial Cancer
PDIGREE Trial in Metastatic Untreated RCC
PDIGREE Trial in Metastatic Untreated RCC

Preview

'GPS' for Breast Cancer Targets Therapy & Improves Aesthetics after Breast Cancer Surgery
'GPS' for Breast Cancer Targets Therapy & Improves Aesthetics after Breast Cancer Surgery
BioZorb's Role in Breast Conserving Surgery
BioZorb's Role in Breast Conserving Surgery
A 3D Target for Radiation Therapy
A 3D Target for Radiation Therapy
Device May Reduce Complications from Breast Cancer Therapy
Device May Reduce Complications from Breast Cancer Therapy
How BioZorb Fits with New Surgical Techniques
How BioZorb Fits with New Surgical Techniques
BioZorb and Oncoplastic Breast Reduction
BioZorb and Oncoplastic Breast Reduction

Preview

Follow the PD-1 pathway
Follow the PD-1 pathway
Learn from a leading expert
Learn from a leading expert
Myeloma2014

Preview

Dr Kenneth Anderson Prof Gareth Morgan Prof Paul Richardson
Dr Kenneth Anderson Prof Gareth Morgan Prof Paul Richardson
Dr Kenneth Anderson Prof Antonio Palumbo Prof Gareth Morgan Prof Jesús San Miguel
Dr Kenneth Anderson Prof Antonio Palumbo Prof Gareth Morgan Prof Jesús San Miguel
Prof Keith Stewart Prof Gareth Morgan Dr Leif L. Bergsagel Prof Antonio Palumbo
Prof Keith Stewart Prof Gareth Morgan Dr Leif L. Bergsagel Prof Antonio Palumbo
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up

Preview

Reassessing strategies and tactics in cancer research and treating cancer in patients: understanding the role of intercellular communication
Reassessing strategies and tactics in cancer research and treating cancer in patients: understanding the role of intercellular communication
Clinical trials in Bladder Cancer/GU Oncology - discussion with Dr. Petros Grivas, Cleveland Clinic at #Annual Meeting15 @Annual Meeting
Clinical trials in Bladder Cancer/GU Oncology - discussion with Dr. Petros Grivas, Cleveland Clinic at #Annual Meeting15 @Annual Meeting
Discussion on Genitourinary Cancers and genomic profiling with Dr. Grivas @Annual Meeting #Annual Meeting15
Discussion on Genitourinary Cancers and genomic profiling with Dr. Grivas @Annual Meeting #Annual Meeting15
Discussion with Dr. Alok Khorana on Pembrolizumab in colorectal cancer #Annual Meeting15
Discussion with Dr. Alok Khorana on Pembrolizumab in colorectal cancer #Annual Meeting15
Discussion with Dr. Alok Khorana on thrombembolism in GI malignancies at #Annual Meeting15
Discussion with Dr. Alok Khorana on thrombembolism in GI malignancies at #Annual Meeting15
Interview at #AACR15 with Jeri Francoeur, Breast Cancer Patient Advocate
Interview at #AACR15 with Jeri Francoeur, Breast Cancer Patient Advocate
RadMedPM

Preview

Canada’s First Magnetic Resonance guided Radiation Therapy (MRgRT) Suite
Canada’s First Magnetic Resonance guided Radiation Therapy (MRgRT) Suite
VJHemOnc

Preview

Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Whole genome sequencing opens door for targeted Waldenström’s therapy
Whole genome sequencing opens door for targeted Waldenström’s therapy
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
Oncololgy1Now

Preview

Punch Line
Punch Line
lung

Preview

Novel immune checkpoint inhibitors
Novel immune checkpoint inhibitors
CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of  nivolumab versus docetaxel
CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel
MET exon 14 splice variants is the oncogenic driver to target
MET exon 14 splice variants is the oncogenic driver to target
The Future for PD pathway inhibitors in NSCLC
The Future for PD pathway inhibitors in NSCLC
AZD9291 for T790M mutant EGFR is well tolerated
AZD9291 for T790M mutant EGFR is well tolerated
TIGER X - Rociletinib for T790M EGFR mutations
TIGER X - Rociletinib for T790M EGFR mutations
CancerTYPEID

Preview

Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)
Case Study: Use of CancerTYPE ID in Cancer of Unknown Primary (CUP)
Managing Costs in Oncology Care
Managing Costs in Oncology Care
CancerTYPE ID in the Clinic Dr. Boccia
CancerTYPE ID in the Clinic Dr. Boccia
Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID
Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID
The bioT3 Platform
The bioT3 Platform
Unclear Diagnoses in Patients with Metastatic Disease
Unclear Diagnoses in Patients with Metastatic Disease

Preview

Reducing opioids in breast cancer surgery using Bupivacaine
Reducing opioids in breast cancer surgery using Bupivacaine
Management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients with breast cancer
Management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients with breast cancer
Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head and Neck Cancer
Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head and Neck Cancer
Scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
Scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
I-SPY 2 and MK-2206 Shows Benefit For Breast Cancer Patients
I-SPY 2 and MK-2206 Shows Benefit For Breast Cancer Patients
Checkpoint Inhibitors in Triple Negative Breast Cancer
Checkpoint Inhibitors in Triple Negative Breast Cancer

Preview

Clinical Treatment Impact of a LOW/LOW Breast Cancer Index (BCI) Result Dr Naughton
Clinical Treatment Impact of a LOW/LOW Breast Cancer Index (BCI) Result Dr Naughton
Breast Cancer Index (BCI) is an objective measure to help women struggling with decisions Dr Naughton
Breast Cancer Index (BCI) is an objective measure to help women struggling with decisions Dr Naughton
Breast Cancer Index (BCI) Validation Includes Both TAM and AI Treated Patients and letrozole
Breast Cancer Index (BCI) Validation Includes Both TAM and AI Treated Patients and letrozole
An Advance in Molecular Medicine to Manage Breast Cancer extended endocrine therapy
An Advance in Molecular Medicine to Manage Breast Cancer extended endocrine therapy
High Risk Does Not Translate to High Benefit From Extended Endocrine Therapy
High Risk Does Not Translate to High Benefit From Extended Endocrine Therapy
Personalizing Cancer Care Beyond 5 Years
Personalizing Cancer Care Beyond 5 Years

Preview

What may be causing heart and kidney issues in an elderly myeloma patient with no bone lesions%3F
What may be causing heart and kidney issues in an elderly myeloma patient with no bone lesions%3F
What is Selinexor?
What is Selinexor?
Myeloma Updates 2015: Post Annual Meeting/EHA/IMWG
Myeloma Updates 2015: Post Annual Meeting/EHA/IMWG

Preview

Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents
Novel Treatment Combinations in Development for AML: The Role of Hypomethylating Agents

Preview

Is there a role for second line therapy in advanced pancreatic cancer?
Is there a role for second line therapy in advanced pancreatic cancer?
Who are the patients that would benefit from pancreatic cancer screening?
Who are the patients that would benefit from pancreatic cancer screening?
Are pancreatic cancer screening tests for the general public likely to be coming soon? And how close are we to finding predictive biomarkers for pancreatic cancer?
Are pancreatic cancer screening tests for the general public likely to be coming soon? And how close are we to finding predictive biomarkers for pancreatic cancer?
Does radiation treatment play a role in the treatment of pancreatic cancer?
Does radiation treatment play a role in the treatment of pancreatic cancer?
In terms of immunotherapy, what is currently being studied in pancreatic cancer?
In terms of immunotherapy, what is currently being studied in pancreatic cancer?
ManagingCML

Preview

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
2015 Annual Meeting Highlights in CML: Addressing Clinical Barriers to Improved Care for CML Patients
2015 Annual Meeting Highlights in CML: Addressing Clinical Barriers to Improved Care for CML Patients
What are the efficacy and safety considerations in using ponatinib?
What are the efficacy and safety considerations in using ponatinib?
What is the most common reason for treatment failure?
What is the most common reason for treatment failure?
Why should I consider second-generation TKIs as a first-line approach?
Why should I consider second-generation TKIs as a first-line approach?
How do we recognize treatment failure or treatment resistance?
How do we recognize treatment failure or treatment resistance?

Preview

ADD-What are myeloma warriors?
ADD-What are myeloma warriors?
ADD-How important is the FDA approval of once weekly dosage of Kyprolis for multiple myeloma patients?
ADD-How important is the FDA approval of once weekly dosage of Kyprolis for multiple myeloma patients?
ADD-How is the IMFs Black Swan Research Initiative working to find a cure for multiple myeloma?
ADD-How is the IMFs Black Swan Research Initiative working to find a cure for multiple myeloma?
ADD-What is the latest on a new drug called selinexor
ADD-What is the latest on a new drug called selinexor
ADD-How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?
ADD-How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?
ADD-If you have myeloma should you undergo tests for DNA sequencing
ADD-If you have myeloma should you undergo tests for DNA sequencing
P2Professional

Preview

ASH 2017: New Drugs and Numerous Drug Combinations in Myeloma
ASH 2017: New Drugs and Numerous Drug Combinations in Myeloma
Treatment News in Lymphoma From ASH 2017
Treatment News in Lymphoma From ASH 2017
Making Treatment Decisions in Myeloma: How Do I Know What’s Right for Me?
Making Treatment Decisions in Myeloma: How Do I Know What’s Right for Me?
ROR1: An Update From ASH 2017
ROR1: An Update From ASH 2017
ASH 2017: CLL Combination Therapy News
ASH 2017: CLL Combination Therapy News
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?
ESOncology

Preview

Radiotherapy-related skin reactions
Radiotherapy-related skin reactions
Malignant fungating wounds
Malignant fungating wounds
Teenage/Young Adult Cancer - most relevant problems in cancer care
Teenage/Young Adult Cancer - most relevant problems in cancer care
Highlights of ABC3 - Advanced Breast Cancer Third International Consensus Conference
Highlights of ABC3 - Advanced Breast Cancer Third International Consensus Conference
BRCA1/2 associated breast cancer Dr Shani Paluch-Shimon
BRCA1/2 associated breast cancer Dr Shani Paluch-Shimon
HPV Vaccination for cervical cancer prevention
HPV Vaccination for cervical cancer prevention
SarahCannon

Preview

Dr. Hamilton on Fox & Friends Discussing New HER2+ Breast Cancer Treatment - Sarah Cannon
Dr. Hamilton on Fox & Friends Discussing New HER2+ Breast Cancer Treatment - Sarah Cannon
Dr. Bendell on MSNBC Discussing Jimmy Carter's Melanoma Diagnosis - Sarah Cannon
Dr. Bendell on MSNBC Discussing Jimmy Carter's Melanoma Diagnosis - Sarah Cannon
Understanding Non-Hodgkin's Lymphoma - Sarah Cannon
Understanding Non-Hodgkin's Lymphoma - Sarah Cannon
Dr. Skip Burris Discusses Advances in Cancer Research on CNN - Sarah Cannon
Dr. Skip Burris Discusses Advances in Cancer Research on CNN - Sarah Cannon
Sarah Cannon Experts on Fox and Friends Discussing Cancer
Sarah Cannon Experts on Fox and Friends Discussing Cancer
Dr. David Spigel on Fox News Discussing Novel Therapies at Annual Meeting® 2015 - Sarah Cannon
Dr. David Spigel on Fox News Discussing Novel Therapies at Annual Meeting® 2015 - Sarah Cannon
AeonGlobal

Preview

Somatic Profiles - NGS Testing
Somatic Profiles - NGS Testing
TakedaOncology

Preview

Does the development of resistant clones in multiple myeloma affect long-term treatment?
Does the development of resistant clones in multiple myeloma affect long-term treatment?
To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?
To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?
Are there practical considerations for long-term treatment of multiple myeloma?
Are there practical considerations for long-term treatment of multiple myeloma?

Preview

Staffing Strategies for Best Practices in Oncology Infusions Ambulatory Clinics
Staffing Strategies for Best Practices in Oncology Infusions Ambulatory Clinics
Ethical Considerations of Precision Medicine for Oncology Nurses
Ethical Considerations of Precision Medicine for Oncology Nurses
Creating an Accurate Home Medication List in an Oncology Outpatient Clinic: Can it be Done?
Creating an Accurate Home Medication List in an Oncology Outpatient Clinic: Can it be Done?
A Model for Global Engagement of Oncology Nurses
A Model for Global Engagement of Oncology Nurses
Advances in Immunotherapy and Patient-Centered Care in a Therapy-Specific Research Setting
Advances in Immunotherapy and Patient-Centered Care in a Therapy-Specific Research Setting
Managing Cytokine Release Syndrome in Immunotherapy Patients in an Ambulatory Clinic
Managing Cytokine Release Syndrome in Immunotherapy Patients in an Ambulatory Clinic
ASHReport

Preview

Uses Of Cord Blood Transplants
Uses Of Cord Blood Transplants
Cord Blood Transplants In Clinical Practice
Cord Blood Transplants In Clinical Practice
Cord Blood Matched & Mismatched Unrelated Donors
Cord Blood Matched & Mismatched Unrelated Donors
Understanding & Using Combo Approaches With CAR T cell Therapy
Understanding & Using Combo Approaches With CAR T cell Therapy
Progressive Disease After Receiving CAR T Cell Therapy
Progressive Disease After Receiving CAR T Cell Therapy
Progression Of Disease & Treatment
Progression Of Disease & Treatment

Preview

Randomized Phase III Trial of Atezolizumab + Bevacizumab  The combination therapy proved efficacious, progression-free survival by PD-L1 group
Randomized Phase III Trial of Atezolizumab + Bevacizumab The combination therapy proved efficacious, progression-free survival by PD-L1 group
Microbiome Effects of Antibodies Can Linger for Up to 60 Days   Push a start date to allow time between antibiotic use and immunotherapy
Microbiome Effects of Antibodies Can Linger for Up to 60 Days Push a start date to allow time between antibiotic use and immunotherapy
Using Microbiome Transplantation or FMT for RCC  They should still benefit from their given immunotherapy with additional supplements
Using Microbiome Transplantation or FMT for RCC They should still benefit from their given immunotherapy with additional supplements
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Subgroup analyses of METEOR
Subgroup analyses of METEOR
CheckMate 025 phase III trial
CheckMate 025 phase III trial

Preview

The Role of PD-L1 Pathway in Cancer Immune Invasion
The Role of PD-L1 Pathway in Cancer Immune Invasion
The Importance of PD-L1 Expressions on Tumor and Immune Cells
The Importance of PD-L1 Expressions on Tumor and Immune Cells

Preview

TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC
TACTICS Trial Demonstrates Benefit With TACE Plus Sorafenib in Unresectable HCC
TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer
TACE New Cancer Region Is Not Failure - TACE + Sorafenib Should Be Continued Even After New Cancer
TACE + Sorafenib May Change Standard in HCC - If Overall Survival Data is Positive then Standard of Care Will Change
TACE + Sorafenib May Change Standard in HCC - If Overall Survival Data is Positive then Standard of Care Will Change
Regorafenib Dose Optimization Study (ReDOS) Weekly escalation Regorafenib 80 to 160 mg-day superior to start dose of 160
Regorafenib Dose Optimization Study (ReDOS) Weekly escalation Regorafenib 80 to 160 mg-day superior to start dose of 160
Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months
Combo Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer 8Response Rate with an Overall Survival of 13-14 months
Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High
Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High
ASTROHN2016

Preview

GC4419 may assist in delivering more effective radiation therapy #hncs16
GC4419 may assist in delivering more effective radiation therapy #hncs16
GC4419 appears to decrease duration of oral mucositis #hncs16
GC4419 appears to decrease duration of oral mucositis #hncs16
Trial Results of Superoxide Dismotase Mimetic GC4419 to Reduce Chemoradiotherapy-induced Oral Mucositis #hncs16
Trial Results of Superoxide Dismotase Mimetic GC4419 to Reduce Chemoradiotherapy-induced Oral Mucositis #hncs16
GC4419 mechanism of action #hncs16
GC4419 mechanism of action #hncs16
Free Tissue Transfer in tongue and oropharynx defects helps intelligibility of speech #hncs16
Free Tissue Transfer in tongue and oropharynx defects helps intelligibility of speech #hncs16
New cost saving technologies for reconstructing mandible after cancer treatment #hncs16
New cost saving technologies for reconstructing mandible after cancer treatment #hncs16
ScrippsHealth

Preview

Greatest impact of immune checkpoint inhibitors in hematologic malignancies
Greatest impact of immune checkpoint inhibitors in hematologic malignancies
Management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies
Management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies
Most common adverse events for  PD-1 and PD-L1 monoclonal antibodies
Most common adverse events for PD-1 and PD-L1 monoclonal antibodies
Real world experience with the novel immune checkpoint inhibitors
Real world experience with the novel immune checkpoint inhibitors
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
Using Biomarkers in Immunotherapy in Head and Neck Cancer.
Pembrolizumab and nivolumab Immunotherapies Show Efficacy in Head and Neck Cancer
Pembrolizumab and nivolumab Immunotherapies Show Efficacy in Head and Neck Cancer
sgo2016

Preview

Toxicity as a Biomarker
Toxicity as a Biomarker
SGO 2016 highlights and trends #SGOmtg
SGO 2016 highlights and trends #SGOmtg
The next 5 years in gynaecologic malignancies treatment #SGOmtg
The next 5 years in gynaecologic malignancies treatment #SGOmtg
SGO Presidential address inspirational #SGOmtg
SGO Presidential address inspirational #SGOmtg
High number of uterine and BRCA mutations from study focusing on endometrial cancer patients #SGOmtg
High number of uterine and BRCA mutations from study focusing on endometrial cancer patients #SGOmtg
Future clinical trials in ovarian cancer #SGOmtg
Future clinical trials in ovarian cancer #SGOmtg
VJOncology

Preview

BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Patient symptom and experience trackers
Patient symptom and experience trackers
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
The switch to biosimilar rituximab at UCH: 12 months on
The switch to biosimilar rituximab at UCH: 12 months on
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML

Preview

ANG1005 shows promise for patients with leptomenigeal disease
ANG1005 shows promise for patients with leptomenigeal disease
Predictive and Prognostic biomarkers for Brain Metastasis
Predictive and Prognostic biomarkers for Brain Metastasis
ANG1005 side effect profile
ANG1005 side effect profile
ANG1005 shows promise in Brain Cancer
ANG1005 shows promise in Brain Cancer
Blood Brain Barrier and TKI in Brain Cancer treatment
Blood Brain Barrier and TKI in Brain Cancer treatment
Treating Brain Metastasis is being redefined due to genomic profiling
Treating Brain Metastasis is being redefined due to genomic profiling

Preview

Patient Testimonial #3 for Breast Cancer Index
Patient Testimonial #3 for Breast Cancer Index
Breast Cancer Index: How Does BCI Work?
Breast Cancer Index: How Does BCI Work?
Patient Testimonial #1 for Breast Cancer Index
Patient Testimonial #1 for Breast Cancer Index
Patient Testimonial #2 for Breast Cancer Index
Patient Testimonial #2 for Breast Cancer Index
What is Breast Cancer Index?
What is Breast Cancer Index?

Preview

Opdivo Does Not Meet Endpoint
Opdivo Does Not Meet Endpoint
Inherited Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
Inherited Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers

Preview

How does this affect treatment?
How does this affect treatment?
Is this truly safe?
Is this truly safe?
Radiation Therapy in Patients with Inflammatory Bowel Disease and Rectal Cancer
Radiation Therapy in Patients with Inflammatory Bowel Disease and Rectal Cancer
How does this affect clinicians today?
How does this affect clinicians today?
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Nomograms on salvage radiotherapy
Nomograms on salvage radiotherapy
News

Preview

VCLS Appoints Carole Jones, Director, Market Access
VCLS Appoints Carole Jones, Director, Market Access
Statement from ASH President Kenneth C. Anderson, MD, on Administration’s Proposed Cuts to NIH
Statement from ASH President Kenneth C. Anderson, MD, on Administration’s Proposed Cuts to NIH
VCLS Appoints Dr. Gopalan Narayanan, Vice-President, Disruptive Biologics
VCLS Appoints Dr. Gopalan Narayanan, Vice-President, Disruptive Biologics
CLEVELAND CLINIC RESEARCHERS REVERSE PROSTATE CANCER DRUG RESISTANCE: Laboratory findings may spur new approach for those resistant to current therapies
CLEVELAND CLINIC RESEARCHERS REVERSE PROSTATE CANCER DRUG RESISTANCE: Laboratory findings may spur new approach for those resistant to current therapies
University of Virginia Cancer Center Joins CancerLinQ® as Participating Practice
University of Virginia Cancer Center Joins CancerLinQ® as Participating Practice
Clinical Practice Guideline Focuses on Molecular Biomarker Testing for Patients with Colorectal Cancer
Clinical Practice Guideline Focuses on Molecular Biomarker Testing for Patients with Colorectal Cancer
LLS

Preview

LLS’s Beat AML Master Trial aligns with the Cancer Moonshot
LLS’s Beat AML Master Trial aligns with the Cancer Moonshot
The Leukemia & Lymphoma Society’s Beat AML Master Trial
The Leukemia & Lymphoma Society’s Beat AML Master Trial
Beat AML initiative addresses the urgent need for a new approach to treat acute myeloid leukemia.
Beat AML initiative addresses the urgent need for a new approach to treat acute myeloid leukemia.
LLS’s leadership role in going on the offensive against acute myeloid leukemia
LLS’s leadership role in going on the offensive against acute myeloid leukemia

Preview

Glioblastoma: A Closer Look
Glioblastoma: A Closer Look
ASH 2016: Importance of Networking with Myeloma Investigators
ASH 2016: Importance of Networking with Myeloma Investigators
ASH 2016: Unique Immune Profiling Method Transforms Patient Care
ASH 2016: Unique Immune Profiling Method Transforms Patient Care
ASH 2016: Significance of Research Collaboration
ASH 2016: Significance of Research Collaboration
ASH 2016: LCI's Impact in Research and Treatment for Blood Cancers
ASH 2016: LCI's Impact in Research and Treatment for Blood Cancers

Preview

Survivorship Care Basics for Colorectal Cancer Survivors
Survivorship Care Basics for Colorectal Cancer Survivors
Poster Presentation Overview: A 12-Week Home-Based Walking Intervention in Patients with Advanced Pancreas Cancer
Poster Presentation Overview: A 12-Week Home-Based Walking Intervention in Patients with Advanced Pancreas Cancer
Importance of Including Diet and Exercise into Discussion with Colorectal Cancer Survivors
Importance of Including Diet and Exercise into Discussion with Colorectal Cancer Survivors
Survivorship Transitions to Adulthood and Using Telemedicine in Rural Areas
Survivorship Transitions to Adulthood and Using Telemedicine in Rural Areas
Importance of Communication Between Clinicians and Survivors
Importance of Communication Between Clinicians and Survivors
TP53 Mutation Carriers: Cancer Genetics in Survivorship Care
TP53 Mutation Carriers: Cancer Genetics in Survivorship Care

Preview

Viral Therapy Results Triggers Race to Complete Clinical Trials
Viral Therapy Results Triggers Race to Complete Clinical Trials
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Viral Therapy May Prove to Be a Transformational Addition to Immuno-Oncology
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Recombinant Measles and Vesicular Stomatitis Virus are Ideal Adjunct to Checkpoint Immunotherapy
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Stress Reducing Beta Blockers Combined With Immunotherapy May Increase Response Rates in Cancer Patients
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Retrospective Analysis Suggests Patients on Beta Blockers May Do Better on Immunotherapy Treatments
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
Higher Stress Levels in Mice Cause a Reduced Response Rate in Immunotherapy
SGO2017

Preview

Presentation Overview: Role of Gynecologic Oncologists in Teaching about the HPV Vaccine
Presentation Overview: Role of Gynecologic Oncologists in Teaching about the HPV Vaccine
Importance of Communicating the Safety and Efficacy of HPV Vaccine
Importance of Communicating the Safety and Efficacy of HPV Vaccine
Abstract Overview: Vaccination Can Protect Children From 6 Different Types of Cancers
Abstract Overview: Vaccination Can Protect Children From 6 Different Types of Cancers
Presentation Overview: HPV Vaccine Champion Training for Gynecologic Oncologists
Presentation Overview: HPV Vaccine Champion Training for Gynecologic Oncologists
Practical Guidlines on How Gynecologic  Oncologists Can Get Involved with HPV Vaccine Outreach
Practical Guidlines on How Gynecologic Oncologists Can Get Involved with HPV Vaccine Outreach
Impact of HPV Vaccine Research in Cancer Prevention
Impact of HPV Vaccine Research in Cancer Prevention
NCCN2017

Preview

Who Should Get Genomic Profilers in Breast Cancer
Who Should Get Genomic Profilers in Breast Cancer
Using Genomic Profiling for Prognoses in  Breast Cancer
Using Genomic Profiling for Prognoses in Breast Cancer
Treatment Trends for  Estrogen Receptor Positive Breast Cancer for 2017
Treatment Trends for Estrogen Receptor Positive Breast Cancer for 2017
Future Research in Biomarkers for Breast Cancer
Future Research in Biomarkers for Breast Cancer
Utilizing Data to Manage MPN in an Evidence Based Approach
Utilizing Data to Manage MPN in an Evidence Based Approach
Treatment Trends for Myeloma in 2017
Treatment Trends for Myeloma in 2017
aacr2017

Preview

The Effect of ER-p53 Combined With Mutant p53
The Effect of ER-p53 Combined With Mutant p53
Repurposing Tamoxifen Therapy for Triple Negative Breast Cancer
Repurposing Tamoxifen Therapy for Triple Negative Breast Cancer
Customizing Therapy Based on p53 Status
Customizing Therapy Based on p53 Status
Abstract Overview: Novel Effect of Tamoxifen Therapy in Breast Cancer
Abstract Overview: Novel Effect of Tamoxifen Therapy in Breast Cancer
Presentation Overview: The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance
Presentation Overview: The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance
Treatment Trends for 2017
Treatment Trends for 2017

Preview

International conference on cancer biology and therapeutics 2017
International conference on cancer biology and therapeutics 2017
Cancer Biology and Therapeutics 2017
Cancer Biology and Therapeutics 2017
GiDebates2017

Preview

The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment
The Impact of Molecular Subsets on Adjuvant and Advanced Disease Treatment
Importance of Early Molecular Testing in Colon Cancer
Importance of Early Molecular Testing in Colon Cancer
Impact of Molecular Testing on Upcoming Clinical Trials
Impact of Molecular Testing on Upcoming Clinical Trials
Debate: What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer?
Debate: What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer?
Debate: Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy?
Debate: Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy?
Novel Endoscopic Management of Pancreaticobiliary Cancers
Novel Endoscopic Management of Pancreaticobiliary Cancers

Preview

Gefitinib versus Vinorelbine+Cisplatin as Adjuvant Treatment in Stage II-IIIA NSCLC
Gefitinib versus Vinorelbine+Cisplatin as Adjuvant Treatment in Stage II-IIIA NSCLC
First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonsquamous NSCLC
First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonsquamous NSCLC
Efficacy and Safety of Lorlatinib in ALK+ NSCLC
Efficacy and Safety of Lorlatinib in ALK+ NSCLC
ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC
ARCHER 1050: Dacomitinib vs Gefitinib for Advanced EGFR Mutation Positive NSCLC
ALEX Trial: Alectinib vs Crizotinib in ALK-Positive NSCLC
ALEX Trial: Alectinib vs Crizotinib in ALK-Positive NSCLC
What’s the Take-Home Message of POLLUX & CASTOR
What’s the Take-Home Message of POLLUX & CASTOR

Preview

Dr. Jame Abraham discusses the NSABP and breast cancer clincial trials
Dr. Jame Abraham discusses the NSABP and breast cancer clincial trials
Dr. Thom George discusses colorectal cancer
Dr. Thom George discusses colorectal cancer
Dr. Peter Lucas discusses clinical trial testing
Dr. Peter Lucas discusses clinical trial testing
Cancer-News

Preview

CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Standard Conversion Rate From Lumpectomy to Mastectomy
Standard Conversion Rate From Lumpectomy to Mastectomy
Reducing The Need For Second Surgery After Lumpectomy: How Will This Affect Data Today?
Reducing The Need For Second Surgery After Lumpectomy: How Will This Affect Data Today?
Cancer Patients Have Limited Understanding of Genomic Test Results
Cancer Patients Have Limited Understanding of Genomic Test Results
Reducing The Need For Second Surgery After Lumpectomy: Why Isn't Everybody Doing This?
Reducing The Need For Second Surgery After Lumpectomy: Why Isn't Everybody Doing This?
Phase III CASPIAN Trial IMFINZI: The Full Trial Design
Phase III CASPIAN Trial IMFINZI: The Full Trial Design
moffitt

Preview

What’s the Next Step for Vyxeos in AML?
What’s the Next Step for Vyxeos in AML?
Vyxeos versus 7 + 3 for Older Patients with High-Risk AML
Vyxeos versus 7 + 3 for Older Patients with High-Risk AML
Impact of Vyxeos on Clinical Practice
Impact of Vyxeos on Clinical Practice
Common Questions Regarding Efficacy and Safety of Vyxeos
Common Questions Regarding Efficacy and Safety of Vyxeos
BeaconMedIC

Preview

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
Overall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)
The MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)

Preview

Denosumab gives clinicians more choices for treating multiple myeloma
Denosumab gives clinicians more choices for treating multiple myeloma
What are the next steps for Denosumab?
What are the next steps for Denosumab?
Is it possible to switch from one bone targeting agent to another
Is it possible to switch from one bone targeting agent to another
Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?
Is it possible to switch from one bone targeting agent to another in Multiple Myeloma?
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
Denosumab More Cost Effective v Zoledronic Acid in Multiple Myeloma
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma
Economic Analysis Denosumab v Zoledronic Acid in Multiple Myeloma

Preview

EGFR Inhibitor Resistant Patients EGFR Antibodies May Play a Role
EGFR Inhibitor Resistant Patients EGFR Antibodies May Play a Role
EGFR Small Molecules v Antibodies In Combination Antibodies better than Small Molecules
EGFR Small Molecules v Antibodies In Combination Antibodies better than Small Molecules
Oncologic Supplements and Diet Correlative Evidence is Incomplete, Safety First
Oncologic Supplements and Diet Correlative Evidence is Incomplete, Safety First
FLAURA Data & Osimertinib High PFS as Front-Line Agent
FLAURA Data & Osimertinib High PFS as Front-Line Agent
Active Patients Equal Better Prognosis and Physically Fit Lung Cancer Patience See Better Outcomes
Active Patients Equal Better Prognosis and Physically Fit Lung Cancer Patience See Better Outcomes
American Cancer Society 2015 Lung Cancer Screening Only 300,000 Patients Screened Per Year
American Cancer Society 2015 Lung Cancer Screening Only 300,000 Patients Screened Per Year

Preview

The Importance of MRD
The Importance of MRD

Preview

Incorporating Different Schedules into Combinations  Use minimum active dose
Incorporating Different Schedules into Combinations Use minimum active dose
Quadruple Agents in Relapse Refractory Myeloma  Capitalizing on synergy & lack of toxicities
Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities
Adding to Lenalidomide to Make it Work Better  Prednisone inhibitors, carfilzomib, and bortezomib
Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib
One Size Does Not Fit All in Myeloma   Clonal Tiding & Complex Heterogeneity
One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity
Early Transplant Confers PFS Benefit, but Not Overall  Stem cell transplant is an option
Early Transplant Confers PFS Benefit, but Not Overall Stem cell transplant is an option
Combinations with RVD Beyond Daratumumab  Data with ixazomib, revlimid, & dexamethasone
Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone

Preview

Lurbinectedin Focus - Small Cell Lung Cancer Virtual Roundtable
Lurbinectedin Focus - Small Cell Lung Cancer Virtual Roundtable
Immunotherapy - Small Cell Lung Cancer Virtual Roundtable
Immunotherapy - Small Cell Lung Cancer Virtual Roundtable
Small Cell Lung Cancer Virtual Roundtable - ROVA-T
Small Cell Lung Cancer Virtual Roundtable - ROVA-T
Small Cell Lung Cancer Virtual Roundtable
Small Cell Lung Cancer Virtual Roundtable
Annual-Meeting

Preview

Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk
Having a Parent, Sibling, or Child with Blood Cancer Increases One’s Own Risk
Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer
Roswell Park Researchers Identify Immune Biomarker of Response in Patients With Advanced Liver Cancer
TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER
TAGRISSO® (OSIMERTINIB) SIGNIFICANTLY IMPROVES OVERALL SURVIVAL IN THE PHASE III FLAURA TRIAL FOR 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer
Add-On Chemo Boosts Survival in High-Risk Endometrial Cancer
Dermatologists can limit skin, hair, nail side effects from cancer therapy
Dermatologists can limit skin, hair, nail side effects from cancer therapy
Niraparib induces responses in late-line, BRCA-negative ovarian cancer
Niraparib induces responses in late-line, BRCA-negative ovarian cancer
EonHealth

Preview

Eon Expert Series + Mark Cuban Press Release
Eon Expert Series + Mark Cuban Press Release
Eon Expert Series + Mark Cuban
Eon Expert Series + Mark Cuban
PharmaMar

Preview

Pascal Besman, COO Pharmamar - PharmaMar to submit New Drug Application (NDA) for lurbinectedin
Pascal Besman, COO Pharmamar - PharmaMar to submit New Drug Application (NDA) for lurbinectedin
Taofeek Owonikoko MD, PhD, MSCR - Lurbinectedin, a potential practice changing drug if approved
Taofeek Owonikoko MD, PhD, MSCR - Lurbinectedin, a potential practice changing drug if approved
Hossein Borghaei, DO, MS - New Drug Application (NDA) for lurbinectedin
Hossein Borghaei, DO, MS - New Drug Application (NDA) for lurbinectedin
Spanish Version - Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Spanish Version - Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial
Luis G. Paz-Ares, MD, PHD Special Presentation June 1st, 2019 McCormick Place Hall D2, 3pm
Luis G. Paz-Ares, MD, PHD Special Presentation June 1st, 2019 McCormick Place Hall D2, 3pm
Melwy

Preview

Cancer Immunotherapy: how to predict results better
Cancer Immunotherapy: how to predict results better
UCSD

Preview

Using Machine Learning Models to Better Predict Bladder Cancer Stages
Using Machine Learning Models to Better Predict Bladder Cancer Stages
alexvarney

Preview

Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Stan

Preview

What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube
What is PFS2 in Advanced NSCLC, and Should we Care_ Unique Analysis of the KEYNOTE-024 trial [720p] - OncologyTube